Proved antibody production
VLA1601 is furthermore a "has been shown to be immunogenic (antibody production) in all vaccinated groups and causes antibodies to the Zika virus based on doses and schedule vaccinations", they added. A Phase 1 study"evaluates the safety and immunogenicity of two different candidate tests for inactivated and adjuvanted alum inocula in 67 healthy adults who have not previously been infected with flavivirus aged 18 to 49 years"they said.
The end of concurrent development
In July 2017, Valneva awarded the exclusive worldwide Emergent BioSolutions license for its vaccine-producing technology. Both companies agreed that the vaccine would be developed until the release of phase I data, with Valneva being responsible for operations.
Otherwise, Emergent has the opportunity to continue the development of the vaccine after obtaining the results of Phase I.
In return, the US taxpayer paid the first milestone payment of 5 million euros and "additional border payments related to the development, marketing and marketing of clinical products up to € 44 million".
View Joint Press Releases Valneve and Emergent BioSolutions: